DA Davidson analyst William Jellison keeps a Buy rating and $36 price target on Phreesia (PHR) while naming the company the firm’s 2025 top pick in Vertical Software. The stock remains “poorly understood” by the market and believed to be a healthcare company, whereas it clearly adheres to a business model and exhibits characteristics most closely aligned with Vertical Software, the analyst tells investors in a research note. Phreesia also has no debt, likely about $50M of free cash flow in 2025, and 2025 revenue growth of 14%, which is third quartile versus 19 other Vertical Software peers, the firm sates, adding that shares trade at enterprise value of just 20x EBITDA vs. a Vertical peer median multiple of 32x.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue